New blood pressure drug HCP1803-4 faces final test
NCT ID NCT07660796
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether a new drug called HCP1803-4 can safely lower blood pressure in adults with essential hypertension. Participants are randomly assigned to receive either the new drug or a control drug. The study measures changes in sitting blood pressure over time to see if the new drug works better or as well as existing options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HCP1803-4
- What this could lead to
- If successful, this could offer a new treatment option for people with high blood pressure, potentially improving blood pressure control.
- What could go wrong
- This is a phase 3 trial, but results may not confirm superiority over existing treatments. Side effects are possible, and individual responses may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Donggguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, 10326, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a heart drug be a new key to controlling high blood pressure?
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control